Corcept Therapeutics vs Ionis Pharmaceuticals
CORT and IONS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CORT and IONS compare
Corcept Therapeutics is the larger company, worth 1.6 times as much as Ionis Pharmaceuticals ($7.9B against $4.8B).
Corcept Therapeutics grew revenue faster over the last twelve months (16.0% versus −0.71% for Ionis Pharmaceuticals).
Corcept Therapeutics keeps more of each dollar of sales as profit, with a net margin of 6.6% compared with −56.9% at Ionis Pharmaceuticals.
Corcept Therapeutics scores higher on the StockData Score (11 against 3 for Ionis Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CORT | IONS |
|---|---|---|
| Size and price | ||
| Market cap | $7.9B | $4.8B |
| Share price | $72.94 | $29.06 |
| Change, 1 year | −7.0% | −60.0% |
| Change, 5 years | 219% | −9.2% |
| Beta (5Y) | 0.58 | 0.68 |
| Employees | 730 | 1,402 |
| StockData Score | ||
| Total score | 11 (better) | 3 |
| Valuation score | 0 | 0 |
| Growth score | 3 (better) | 2 |
| Performance score | 2 (better) | 0 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 174× | – |
| P/S | 9.5× | 5.0× (better) |
| P/B | 11.2× (better) | 12.3× |
| EV/EBITDA | 937× | – |
| P/FCF | 73.7× | – |
| FCF yield | 1.4% (better) | −12.8% |
| Fair value | $16.26 | $27.99 |
| Margin of safety | −349% | −3.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 16.0% (better) | −0.71% |
| Revenue growth, 5Y average | 16.6% (better) | 5.3% |
| Net income growth (TTM) | −58.7% | – |
| EPS growth (TTM) | −62.5% | – |
| EPS growth, 5Y average | −0.72% | – |
| Profitability | ||
| Gross margin | 98.3% (better) | 98.2% |
| Operating margin | 0.77% (better) | −58.8% |
| Net margin | 6.6% (better) | −56.9% |
| FCF margin | 12.9% (better) | −64.2% |
| Return on equity | 8.2% (better) | −108% |
| Return on invested capital | 1.9% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −29.4× |
| Current ratio | 2.86 | 5.43 (better) |
| Altman Z-score | 28.24 (better) | 0.22 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | 0.54% | – |
| Shareholder yield | 0.54% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 76.2% | 108% |
| Held by insiders | 14.4% | 0.80% |
| Insider net buying, 12 months | −$93.9M (better) | −$114M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 9.9% | 12.8% |
Go deeper
- CORT stock overview
- CORT income statement
- CORT valuation and score
- IONS stock overview
- IONS income statement
- IONS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.